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a b s t r a c t
The pharmacophoric model using ADLR procedure, based on pyrazolo[5,1-c][1,2,4]benzotriazine system,
studied in our laboratory, allowed us to identify the essential interaction points (HBp-1, HBp-2, and Lp-1)
and the important areas for affinity modulation (HBp-3 and Lp-2) for binding recognition at benzodiaz-
epine (Bzs) site of GABAA receptors (GABAA-Rs). In this work ADLR method is used to rationalize the affin-
ity data of 23 new compounds and to improve the knowledge on HBp-3 area, hydrogen bond area. Among
these new compounds emerge the pyrrolo derivatives (18, 25, 28, 34, and 37) for their good affinity value
(14.9 > Ki(nM) > 63.0). In the orientations proposed by ADLR, the NH moiety of the pyrrole ring, indepen-
dently of the position in the pyrazolobenzotriazine core, fits in HBp-3 area and points out the acceptor
feature of this hydrogen bond area, already known as donor area. Unexpectedly, the oxygen atom of
the furane ring does not form efficient hydrogen bond with the same area, probably for an imperfect dis-
tance. The size of substituent at position 8 is important but not necessary for the receptor recognition, in
fact the interdependence between the features of the 3- and 8-substituent’s is again verified, (i.e., com-
pound 20 vs 32).
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
The c-aminobutyric (GABA)-ergic system is the most important
inhibitory mechanism in the adult mammalian brain.1 The GABA
neurotransmitter binds to GABAA receptors (GABAA-Rs), members
of the Cys-loop family of ligand gated ion channels (LGICs) and
to metabotropic G-protein-coupled GABAB receptors.2 GABAA-Rs
are pentameric trans-membrane proteins formed by a combination
of 19 different subunits (a1–6, b1–3, c1–3, d, e, h, p, and q1–3)
with the most common composition being of two single alpha sub-
units, two single beta subunits, and one gamma subunit a2b2c.3
The combination of the isoforms a1–3, 5, b2/3, and c2 form a
subset of GABAA-Rs (a1b2c2, a2b3c2, a3b3c2, and a5b3c2)
modulated by benzodiazepines (Bzs) and by non-benzodiazepine
ligands belonging to several chemical classes. The Bz binding site
is located at the interface of an a and a c subunit and its pharma-
cology is mainly determined by the isoforms of these two subunits.
Subunit b, although needed to generate a functional GABA gated
ion channel, does not affect the sensitivity to the Bz site. Using
genetically engineered mice and comparing drug-induced behav-
ioral responses in mutated and wild-type mice, with respect to
diazepam,4–6 GABAA-R subtype functions have been identified.
The a1b2c2 receptors mediate the sedative, anterograde amnesic
and anticonvulsant actions of diazepam.7–9 The anxiolytic-like ef-
fect and the muscle relaxant activities are mediated by the
a2bc2 and a3bc2 receptors even if the a3-containing GABAA-Rs
seem to be involved in the inhibitory input for the dopaminergic
system.10–12 The a5bc2 receptors, that are preferentially localized
in the hippocampus, seem to influence learning and memory.1
Currently, the unified pharmacophore/receptor model for li-
gands at the Bzs site on the GABAA-Rs developed by Cook et al.,13
has been updated14 and correlated with a comparative model15
to individuate residues relative to descriptors of the pharmaco-
phore/receptor model.
To increase our understanding of the requirements of the Bzs
site on GABAA-R, we have developed a pharmacophoric model
based on pyrazolo[5,1-c][1,2,4]benzotriazine ligands,16 using ADLR
procedure. This procedure allowed us to identify the essential
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interaction points for binding recognition (HBp-1, HBp-2, and Lp-1)
and the important areas for affinity modulation (HBp-3 and Lp-2)
of the pyrazolobenzotriazine system, Figure 1.
At the same time, we elaborated structure–activity/affinity rela-
tionships for the pyrazolobenzotriazine system 3-, 8-disubstituted,
identifying the heteroaryl groups, the thienylmethoxycarbonyl
group17 the iodine atom,18 and the furoyl group19 as better 3-sub-
stituents,20 and, as 8-substituents, the groups endowed with differ-
ent electronic/steric features (alkyl, thioalkyl, alkyloxy, halogen,
aryloxy, and difluoromethoxy).16,21–23 Among these compounds,
it was very intriguing to modify the 8-aryloxy derivatives for
which it was hypothesized that the 8-oxygen atom engaged a
hydrogen bond interaction with the HBp-3 area.16 In this paper
we have decided to investigate the 8-aryl/heteroaryl derivatives,16
maintaining at position 3 the better previously identified substitu-
ents. These modifications (introduction at position 8 of aryl/het-
eroaryl rings) permit us to evaluate whether the HBp-3 area is
involved or if other receptor interactions can occur (p–p stacking,
hydrophobic interaction. . .) and to measure the size and shape of
lipophilic regions Lp-1 and Lp-2.
2. Chemistry
All compounds described here are listed in Table 1 (chemical
data).
Figure 1. Overlapping of ligand conformations following the ADLR procedure: the
figure shows the essential interaction points for binding recognition (yellow circles)
and the important areas for affinity modulation (blue circles).
Table 1
Chemical data for new synthesized compounds
N
N
COOEt
NH2
NO2
O
O-
N
N
N+
N
R3
R8
3-28, 30, 32-37, 40-42 39
Compda R3 R8 Yield (%) Mp C (recryst. solvent)
3 H 2-OMePh 60 190–192 (ethanol)
4 H 4-OMePh 54 196–197 (ethanol)
5 H 4-Py 52 220–222 (ethanol)
6 H 2-Thienyl 65 200–202 (ethanol)
7 H 3-Thienyl 73 206–207 (ethanol)
8 H 2-Furyl 67 201–202 (ethanol)
9 H 1-Boc-2-pyrrolyl 70 196–198 (ethanol)
10 I 2-OMePh 40 212–214 (ethanol)
11 I 2-OHPh 35 250–251 (ethanol)
12 I 4-OMePh 45 234–236 (ethanol)
13 I 4-Py 27 267–269 (ethanol)
14 I 2-Thienyl 54 247–248 (ethanol)
15 I 3-Thienyl 45 258–259 (methoxyethanol)
16 I 2-Furyl 50 215–216 (ethanol)
17 I 1-Boc-2-pyrrolyl 45 207–208 (ethanol)
18 I (1H)-2-Pyrrolyl 30 >300 (ethanol)
19 3-Thienyl Ph 25 237–238 (ethanol)
20 3-Thienyl 4-OMePh 56 250–252 dec (chromatography)
21 3-Thienyl 2-Thienyl 30 229–230 (methoxyethanol)
22 3-Thienyl 3-Thienyl 25 233–234 (methoxyethanol)
23 3-Thienyl 2-Furyl 84 240–241 (ethanol)
24 3-Thienyl 1-Boc-2-pyrrolyl 45 196–198 dec (ethanol)
25 3-Thienyl (1H)-2-Pyrrolyl 77 >300 (ethanol)
26 2-Furyl 3-Thienyl 37 249–250 (chromatography)
27 1-Boc-2-pyrrolyl 3-Thienyl 57 194–195 dec (ethanol)
28 (1H)-2-Pyrrolyl 3-Thienyl 72 219–220 (ethanol)
30 CO-2-furyl I 30 233–234 (chromatography)
32 COOCH2-2-thienyl 4-OMePh 21 200–202 (chromatography)
33 COOCH2-2-thienyl 1-Boc-2-pyrrolyl 80 138–140 dec (ethanol)
34 COOCH3 (1H)-2-Pyrrolyl 69 >300 (ethanol)
35 CO-2-furyl 4-OMePh 21 258–259 (chromatography)
36 CO-2-furyl 1-Boc-2-pyrrolyl 73 184–186 dec (ethanol)
37 CO-2-furyl (1H)-2-Pyrrolyl 78 >300 (ethanol)
39 COOEt 2-furyl 90 140–142 (ethanol)
40 COOH 2-furyl 58 279–280 (ethanol)
41 COOCH2-2-thienyl 2-Furyl 23 215–216 (ethanol)
42 CO-2-furyl 2-Furyl 35 230–233 dec (ethanol)
a Compound 1–2, 29, 31, and 38 known, see chemical section for references. Compound 39, ethyl 1-(2-nitro-5-fur-2-ylphenyl)-5-aminopyrazole-4-carboxylate.
G. Guerrini et al. / Bioorg. Med. Chem. 19 (2011) 3074–3085 3075
Author's personal copy
The Suzuki coupling reaction on suitable iodinate starting
material was used for the synthesis of all 3-aryl-, 8-aryl-, and
3,8-diarylderivatives. As reported in Scheme 1, the 8-iodopyrazol-
o[5,1-c][1,2,4]benzotriazine 5-oxide,18 1, was used to obtain the
8-aryl derivatives 3–9, using the suitable arylboronic acid.
The reaction with 2-furylboronic acid produced several prob-
lems, and for the synthesis of compound 8, the most versatile
and stable potassium 2-furantrifluoroborate in presence of the pal-
ladium catalyst, palladiumchloride (diphenylphosphine-ferrocene)
PdCl2(dppf)CH2Cl2 was used as the coupling partner.24,25 (All the
3- and/or 8-(2-furyl) derivatives were synthesized following this
procedure). Compounds 3–9 were in turn iodinated at position 3
with ceric ammonium nitrate (CAN) and iodine26 to give deriva-
tives 10, 12–17 which are useful for structure–affinity relation-
ships. The demethylation of derivative 10 with CH2Cl2/BBr3 gave
the corresponding 2-hydroxyphenyl derivative 11, while the
deprotection of 17 was realized with NaOCH3/CH3OH in THF,27 to
give 18. The starting material 3-(3-thienyl)-8-iodopyrazolo[5,1-
c][1,2,4]benzotriazine 5-oxide,22 2, was instead used to obtain
derivatives 19–24. The deprotection of 24was realized in the same
previously described conditions,27 and compound 25was obtained.
To obtain the 8-(3-thienyl)-3-heteroaryl substituted deriva-
tives, 26–27 (Scheme 2), compound 15 was used as starting mate-
rial for the Suzuki coupling. The deprotection of 27 afforded the
pyrrole derivative 28.
Scheme 3 depicts the synthetic pathway for obtaining deriva-
tives 32–37. The starting material is 3-carboxy-8-iodopyrazol-
o[5,1-c][1,2,4]benzotriazine 5-oxide, 29,22 that was reacted by a
Friedel–Craft reaction with thionyl chloride, SnCl4, and furane19
to obtain the new 3-(fur-2-ylcarbonyl)-8-iodopyrazolo[5,1-c]-
[1,2,4]benzotriazine 5-oxide, 30.
Following a described procedure, compound 29 was also used
to obtain 3-(2-thienylmethoxycarbonyl)-8-iodopyrazolo[5,1-c]-
[1,2,4]benzotriazine 5-oxide, 31.22 Both compounds 30 and 31
were subjected to Suzuki coupling and derivatives 32, 33, 35, and
36 were synthesized. The treatment of derivative 33 with
NaOCH3/CH3OH caused, at the same time, pyrrole deprotection
and trans-esterification, producing derivative 34. In the same
N
N+
N
N
I R3
O-
N
N+
N
N
H
O-
Ar/Het
N
N+
N
N
O-
Ar/Het
S
N
N
I
CH3
CH3
N° 8-Ar/Het 
3 2-OMe-Ph 
4 4-OMe-Ph 
5 4-Py 
6 2-thienyl 
7 3-thienyl 
8 2-furyl 
9 1-Boc-2-pyrrolyl 
N° 8-Ar/Het 
10 2-OMe-Ph 
11 2-OH-Ph 
12 4-OMe-Ph 
13 4-Py 
14 2-thienyl 
15 3-thienyl 
16 2-furyl 
17 1-Boc-2-pyrrolyl 
18 1(H)-2-pyrrolyl 
N° 8-Ar/Het 
19 Ph 
20 4-OMe-Ph 
21 2-thienyl 
22 3-thienyl 
23 2- furyl 
24 1-Boc-2-pyrrolyl 
25 1(H)-2-pyrrolyl iv
2, R3=3-thienyl 
1-2 a
1, R3=H 
3-9
19-25
ii
10-18i
iii
iv
Scheme 1. For compound 1 see,18 for compound 2 see22 Reagents: (i) Suzuki conditions, Arylboronic acids, ethanol abs, (PPh3)4Pd tetrakis(triphenylphosphine)palladium (0),
sodium carbonate 2 M; for synthesis of derivatives 8 and 23, potassium 2-furyltrifluoroborate, n-propanol, TEA, PdCl2(dppf); (ii) I2/CAN/CH3CN; (iii) for hydrolysis of
compound 10, CH2Cl2/BBr3; (iv) for deprotection of N-Boc derivatives (17 and 24) THF/MeONa.
N
N+
N
N
I
O-
S
N
N+
N
N
O-
Ar/Het
S
i
N° 3-Ar/Het 
26 2-furyl 
27 1-Boc-2-pyrrolyl 
28 2-pyrrolyl 
15 
ii
Scheme 2. Reagents: (i) Suzuki conditions, potassium 2-furyltrifluoroborate, n-propanol, TEA, PdCl2(dppf) and N-(Boc)pyrrole-2-boronic acid, ethanol abs, (PPh3)4Pd
tetrakis(triphenylphosphine)palladium (0), sodium carbonate 2 M; (ii) for deprotection of N-Boc derivative (27) THF/MeONa.
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reaction conditions, in derivative 36, the removal of N-Boc group
was selective and derivative 37 was obtained. The reaction of cou-
pling of the furyl ring at position 8 on compounds 30 and 31, with
potassium 2-furantrifluoroborate gave very low yields and with a
heavy work-up, thus the synthesis of compounds 41–42 was made
with an alternative synthetic way, Scheme 4. The intermediate
ethyl 1-(2-nitro-5-iodophenyl)-5-aminopyrazole-4-carboxylate
38,22 was used as starting material to introduce the 2-furyl group,
N
N+
N
N
O-
Ar/Het
R3
ii
N
N+
N
N
O-
I
R3
N
N+
N
N
O-
I
COOH
i
N
N+
N
N
O-
R3O
iii
41 R3= COOCH2(2-thienyl) 
42 R3=CO-2furyl 
N° R3 8-Ar/Het
32 COOCH2-2-thienyl 4-OMe-Ph 
33 COOCH2-2-thienyl 1-Boc-2-pyrrolyl 
34 COOCH3 1(H)-2-pyrrolyl
35 CO-2furyl 4-OMe-Ph 
36 CO-2furyl 1-Boc-2-pyrrolyl 
37 CO-2furyl 1(H)-2-pyrrolyl
30 R3=CO-2furyl 
31a R3= COOCH2(2-thienyl) 
29a 
iv
iv
Scheme 3. For compound 29 and 31 see22: Reagents: (i) Friedel–Craft reaction on 29, 3-carboxy-8-iodopyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide,22 to obtain 30: thionyl
chloride/CH2Cl2/SnCl4/furane; starting from 29, following a procedure described in22 to obtain 31; (ii) Starting material 30 or 31,22 reacted in Suzuki conditions: 4-
methoxyphenylboronic acid for compound 32 and 35, N-Boc-2-pyrrolylboronic acid for compounds 33 and 36, ethanol abs, tetrakis, sodium carbonate 2 M; (iii) potassium 2-
furyltrifluoroborate, n-propanol, TEA, PdCl2(dppf); (iv) for deprotection of N-Boc derivatives (33 and 36) THF/MeONa. In case of derivative 33 in this reaction condition a
trans-esterification occurred, obtained compound 34.
N
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I COOEt
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COOHO
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NO2
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O
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iii
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39 
41 
42 
40 
38a 
Scheme 4. For 38.22 Reagents: (i) potassium 2-furantrifluoroborate, PdCl2(dppf), TEA; (ii) 10% NaOH solution, diglyme; (iii) NEt3, i-butylchloroformate, 2-thiofenemethanol;
(iv) CH2Cl2, Cl3CCN, PPh3, SnCl4, and furane.
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using again potassium 2-furantrifluoroborate and palladium chlo-
ride(diphenylphosphine ferrocene) PdCl2(dppf)CH2Cl2 and 39
was obtained in good yield.
The next cyclization in alkali medium28 gave the 3-carboxy-8-
(2-furyl)pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide 40, that was
esterified by the mixed anhydride method (triethyl amine/i-butyl-
chloroformate and 2-thiophenmethanol), to yield compound 41.
The same compound 40 was transformed into corresponding acid
chloride in mild conditions, by treatment with trichloroacetonitrile
and triphenylphosphine in methylene chloride29; this acyl chloride
was not isolated, but subjected to a Friedel–Craft reaction with
SnCl4 and furane to obtain derivative 42.
3. Results and discussion
3.1. Biological results
The affinity at the Bz site on GABAA-R of the new synthesized
compounds was evaluated by their ability to displace [3H]flu-
mazenil (Ro 15-1788) from its specific binding in bovine brain
membrane.19 The affinity was expressed as Ki only for those com-
pounds inhibiting radioligand binding by more than 80% at fixed
concentrations of 10 lM.
From the binding results reported in Table 2, some observations
arise. The new tested compounds show receptor recognition with a
Ki range of 14.9–2480 nM. Compounds 3–9 as well as compound
40, (Table 1) were not tested because previous reports indicate that
these types of derivatives have no receptor recognition.21
Among the 3-iodopyrazolo[5,1-c][1,2,4]benzotriazine 5-oxides,
bearing various aryl/heteroaryl rings at position 8, 10–18, the fea-
tures of ring moiety are very important. In fact, the optimization of
the 8-phenyl derivative, A27,16 (Ki = 966 nM), that is, compounds
10 and 12, allow a threefold higher binding affinity: 10,
Ki = 305 nM and 12 Ki = 241 nM. These compounds have a methoxy
group in the phenyl ring (ortho- and para-position, respectively)
that could reinforce the interaction with receptor protein.16
A more hydrophilic substituent at position 8 is detrimental for
the binding as shown for compound 11 (Ki = 2480 nM), obtained
from demethylation of 10 and for the 8-(4-pyridyl)-derivative
(Ki = 2380 nM), compound 13. The isosteric replacement of the
8-phenyl ring with five-membered heteroaryl rings 2-, 3-thienyl,
2-furyl and (1H)-2-pyrrolyl gave compounds 14–16 and 18. The
best affinity was shown by derivative (1H)-2-pyrrolyl, 18
(Ki = 25 nM), that contains a hydrogen bond donor atom (NH).
Among the other heteroaryl rings, only the 8-(3-thienyl) derivative
15 is endowed with good binding affinity (Ki = 56 nM) compared to
the 8-(2-thienyl), 14, Ki = 202 nM and the 8-(2-furyl), 16,
Ki = 190 nM. These results suggest that the smaller size of the 8-
substituents versus phenyl ring (Ki = 966 nM) permits better recep-
tor interaction.
In the series of the 3-thienyl derivatives (19–23, 25) the intro-
duction at position 8 of aromatic/heteroaromatic rings gave useful
information. The 8-phenyl derivative 19 shows a poor binding
affinity (Ki = 642 nM), as well as the 8-(4-OCH3phenyl) derivative,
20, Ki = 817 nM. When in position 8 was introduced a five-mem-
bered ring, 2-, 3-thienyl, 2-furyl and (1H)-2-pyrrolyl, 21–23 and
25, the receptor recognition falls in the range of 370–19.4 Ki(nM),
confirming again the importance of ring size. In particular, the
need of hydrogen bond donor moiety (NH pyrrole) is evidenced
as for compound 25 (Ki = 19.4 nM), while the presence of an accep-
tor moiety (furane oxygen) gave weak affinity (23, Ki = 209 nM).
We thought that it might be useful to invert the substituents of
positions 3 and 8 of compounds 23 and 25 to evaluate the influence
of their interchangeability in receptor protein recognition, thus
obtaining compounds 26 and 28. The various orientations that
the pyrazolobenzotriazine scaffold assumes, when selected by
ADLR model, show that the substituents at position 3 and 8 can
interact indiscriminately with the pharmacophoric points Lp-1 or
Lp-2 in case of lipophilic moiety and HBp-1, HBp-2, or HBp-3 in
case of a moiety able to form a hydrogen bond interaction.16,23 This
would explain the good affinity shown by 3-(2-furane derivative),
26 (Ki = 26.9 nM) compared to its isomer 23 (8-(2-furane deriva-
tive, Ki = 209 nM), that probably has less interaction strength. The
two pyrrole derivative isomers, instead, have good affinity: 3-
(1(H)-2-pyrrol-) derivative 28, Ki = 48.3 nM and 8-(1(H)-2-pyrrol-
) derivative 25, Ki = 19.4 nM. (We are going to rationalize these re-
sults in the next molecular modeling section).
The (hetero)aryl rings at position 8 in the 3-ester derivatives,
32–34, 41, were chosen considering the influence, positive or neg-
ative, which they have in the two previous series. In the 3-ester
series the negligible influence of the ring size at position 8 was
seen, in fact the affinity value is in the same order of magnitude
(14.96 Ki(nM) 6 54.8) for all compounds, except derivative 33,
(Ki = 395.4 nM). The presence of a six-membered ring (para-
methoxyphenyl), as in derivative 32, or five-membered ring, com-
pound 41, confers quite comparable affinity values, 32 Ki = 29.4 nM
and 41 Ki = 54.8 nM. When position 8 was substituted with a 2-
(1H)-pyrrolyl, as in the case of the 3-methoxycarbonyl derivative
34, the affinity value was the best, Ki = 14.9 nM. The NH pyrrole
protection, as in compound 33, reduced the affinity value confirm-
ing the importance of the NH pyrrole in the binding. Thus, the
importance of anchorage of the 3-ester group is again confirmed17
and the affinity modulation due to substituent at position 8 is
emphasized.16
The importance of the type of 8-substituent in the 3-furoyl
derivatives, 35, 37, 42 that show binding affinity values in the
Table 2
BZR ligand affinity of new 8-aryl-/heteroarylpyrazolo[5,1-c][1,2,4]benzotriazine 5-
oxide 3-substituted
O-
N
N
N+
N
R3
R8
N R3 R8 Ki (nM) a
A27b I Ph 966 ± 95
10 I 2-OMePh 305 ± 29.3
11 I 2-OHPh 2480 ± 120
12 I 4-OMePh 241 ± 23.2
13 I 4-Py 2380 ± 190
14 I 2-Thienyl 202 ± 20
15 I 3-Thienyl 56 ± 4.9
16 I 2-Furyl 190 ± 22
18 I (1H)-2-Pyrrolyl 25 ± 2.4
19 3-Thienyl Ph 642 ± 62.6
20 3-Thienyl 4-OMePh 817.0 ± 16.7
21 3-Thienyl 2-Thienyl 370 ± 35.7
22 3-Thienyl 3-Thienyl 357 ± 33.9
23 3-Thienyl 2-Furyl 209 ± 20
25 3-Thienyl (1H)-2-Pyrrolyl 19.4 ± 2.8
26 2-Furyl 3-Thienyl 26.9 ± 2.5
28 (1H)-2-pyrrolyl 3-Thienyl 48.3 ± 6.1
32 COOCH2-2-thienyl 4-OMePh 29.4 ± 1.8
33 COOCH2-2-thienyl 1-Boc-2-pyrrolyl 395.4 ± 39
34 COOMe (1H)-2-Pyrrolyl 14.9 ± 1.1
41 COOCH2-2-thienyl 2-Furyl 54.8 ± 4.1
35 CO-2-furyl 4-OMePh 238.67 ± 18
37 CO-2-furyl (1H)-2-Pyrrolyl 63.0 ± 5.5
42 CO-2-furyl 2-Furyl 856.9 ± 4.2
a Ki value are means ± SEM of five determinations.
b See Ref. 16.
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range of 63 6 Ki(nM) 6 856 is again verified. Compound 37, the 8-
(1H)-2-pyrrolyl emerges for its good affinity, Ki = 63 nM.
From binding results it is possible assert that compounds bear-
ing the (1H)-2-pyrrolyl moiety are very good ligands (18, 25, 28,
34, and 37) in each series, suggesting the critical role of a hydrogen
bond donor (pyrrole NH) in receptor recognition. Good affinity
values were also identified for compounds bearing acceptor atom
moiety (26, 32, and 41) if only by having the suitable substituent
in the complementary position. Moreover, the size of the substitu-
ent at position 8 is very important only in the 3-iodine-, 3-hetero-
aryl-, and 3-furoylderivative, while it is negligible in the 3-ester
series.
3.2. Molecular modeling
The ADLR method16,23 was used here to rationalize the affinity
data and to improve our knowledge of the HBp-3 area. Among
the compounds endowed with better binding affinity, emerge
derivatives with the pyrrole moiety in position 8 or 3 (18, 25, 34,
37, and 28). In the overlapping performed by ADLR, the pyrrole ring
fits in the HBp-3 area permitting the NH to form hydrogen bond
interaction, independently of the position of the pyrrole moiety
in the pyrazolobenzotriazine core (see Fig. 2).
When the pyrrole ring is replaced with furane (16, 23, 42, 41,
and 26, Figs. 3 and 4) bearing a potential hydrogen bond acceptor
atom (O), ADLR oriented the furane oxygen mainly toward the
HBp-3 area. As depicted in Figure 3,compounds 16, 23, and 42
present the furane moiety in this mode, but the lower affinity value
of compounds (Ki = 190, 209, and 856 nM, respectively) could be
due to a reduced hydrogen bond force or no efficient interaction
with LP-1 area (for 16 and 23) and steric hindrance for 42. Unex-
pectedly, compound 26 (isomer of compound 23) presents a differ-
ent orientation proposed by ADLR (Fig. 4).
The thiophene ring efficiently interacts with the lipophilic area
Lp-1, justifying the best affinity (Ki = 26.9 nM). Compound 41 bear-
ing an ester group (the 2-thienylmethoxycarbonyl group) at posi-
tion 3 shows a good affinity value (Ki = 54.8 nM) according to the
fact that the ester group contributes significantly to receptor
anchorage as previously stated,16 interacting with the lipophilic
area Lp-1 or Lp-2 depending on the orientation (A or B), see Figure 5.
Figure 2. Compounds 18, 25, 28, 34, and 37 in the pharmacophoric model performed by ADLR. The pyrrole ring fits in the HBp-3 area permitting the NH moiety to form
hydrogen bond interaction, independently of the position of the pyrrole moiety in the pyrazolobenzotriazine core.
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The importance of the anchorage by the ester group is also evi-
denced in compound 32 (Ki = 29.4 nM), in which the presence of a
large size group at position 8 is not binding for affinity, Figure 5.
4. Conclusion
In previous studies it was hypothesized that the 8-oxygen atom
of the 8-aryloxypyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide deriv-
atives engaged hydrogen bond interaction with the HBp-3 area.16
On the other hand, the idea/hypothesis that this HBp-3 was a
bifunctional area arose when the CGS 9698 compound, used to val-
idate our pharmacophoric model with respect to Cook’s ‘unified
pharmacophore/receptor model’, showed hydrogen bond interac-
tion with the same area. In this study, this hypothesis is confirmed
since the NH group of the pyrrole ring engages a strong hydrogen
bond interaction with HBp-3. The fact that the furane derivatives
(16, 23, and 42) do not have a good binding, despite the ability
to form a hydrogen bond interaction through the oxygen atom,
could be due to an imperfect distance from hydrogen bond donor
in the HBp-3 area.
In a preliminary study (data not published) derivatives bearing
a phenylethylamine moiety (-NHCH2Ph) at position 8 of pyra-
zolobenzotriazine system were endowed with very good binding
affinity (in a range of 0.1 nM), thus the synthesis of 8-NH isoster
of 8-OAr16 will be the object of our next research project.
5. Experimental
5.1. Chemistry
Melting points were determined with a Gallenkamp apparatus
and were uncorrected. Silica gel plates (Merck F254) and silica gel
60 (Merck 70–230 mesh) were used for analytical and column
chromatography, respectively. The structures of all compounds
were supported by their IR spectra (KBr pellets in nujol mulls, Per-
kin–Elmer 1420 spectrophotometer) and 1H NMR data (measured
with a Bruker 400 MHz). Chemical shifts were expressed in d
ppm, using DMSO-d6 or CDCl3 as solvent. The chemical and physi-
cal data of new compounds are shown in Tables 1; all new com-
pounds possess a purity P95%: microanalyses were performed
with a Perkin–Elmer 260 analyzer for C, H, N.
5.2. General procedure for the synthesis of3–7, 9, 19–22, 24, 27,
32–33, 35–36
Tetrakis(triphenylphosphine)palladium (0) (20 mg, 0.017 mmol)
and the suitable iodopyrazolo benzotriazine (0.15 mmol) were
combined in anhydrous tetrahydrofurane (5.0 mL). The starting
materials were: compound 1,18 for the synthesis of derivatives
Figure 3. Compounds 16, 23, 42 in the pharmacophoric model performed by ADLR. The furane ring is oriented toward the HBp-3, but a reduced hydrogen bond force in the
HBp-3 area or no efficient interaction with Lp-1 area (16 and 23) and a steric hindrance (42) are responsible of a low affinity (16, Ki = 190 nM; 23, Ki = 209 nM; 42,
Ki = 856 nM).
Figure 4. Compounds 26 in the pharmacophoric model performed by ADLR:
unexpected orientation of the furane ring; the driving force of the binding is due to
lipophilic interaction of thiophene ring.
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3–7, 9; compound 2,22 for the synthesis of derivatives 19–22, 24;
compound 15 (see below) for the synthesis of derivative 27; com-
pound 30 for the synthesis of 35 and 36; compound 31,22 for the
synthesis of derivatives 32 and 33. The solution of the suitable
arylboronic acid (0.23 mmol, 1:1.5) in absolute ethanol and aque-
ous sodium carbonate (2 M, 2 mL) were added and the reaction
was maintained at 25–70 C (see the exact condition in each com-
pound) and monitored by TLC. The final suspension was treated
with water, filtrated to crude final product and purified by recrys-
tallization by suitable solvent.
5.2.1. 8-(2-Methoxyphenyl)pyrazolo[5,1-c][1,2,4]benzotriazine
5-oxide (3)
From 1,18 and 2-methoxy phenylboronic acid, 4 h, room
temperature. Yellow crystals; TLC eluent: diisopropyl ether/cyclo-
hexane 8:3 v/v; 1H NMR (DMSO-d6) d 8.48 (m, 2H, H-6 and H-9);
8.29 (d, 1H, H-2); 7.87 (dd, 1H, H-7); 7.53 (m, 2H, H-4 and H-6
phenyl); 7.25 (d, 1H, H-3 phenyl); 7.16 (t, 1H, H-5 phenyl); 6.92
(d, 1H, H-3); 3.85 (s, 3H, OCH3). Anal. C, H, N.
5.2.2. 8-(4-Methoxyphenyl)pyrazolo[5,1-c][1,2,4]benzotriazine
5-oxide (4)
From 1,18 and 4-methoxyphenylboronic acid, 3 h, room temper-
ature. Yellow crystals; TLC eluent: toluene/ethyl acetate/acetic acid
8:2:1 v/v/v; 1H NMR (DMSO-d6) d 8.48 (m, 2H, H-6 and H-9); 8.31
(d, 1H, H-2); 8.05 (dd, 1H, H-7); 7.92 (d, 2H, H-2 and H-6 phenyl);
7.15 (d, 2H, H-3 and H-5 phenyl); 6.92 (d, 1H, H-3); 3.85 (s, 3H,
OCH3). Anal. C, H, N.
5.2.3. 8-(4-Pyridyl)pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide
(5)
From 1,18 and 4-pyridin boronic acid, 3 h, reflux temperature.
Yellow crystals; TLC eluent: toluene/ethyl acetate/acetic acid
8:2:1 v/v/v; 1H NMR (DMSO-d6) d 8.85 (m, 2H, H-2 and H-6 pyri-
dine); 8.70 (m, 2H, H-6 and H-9); 8.18 (d, 1H, H-2); 7.90 (dd, 1H,
H-7); 7.70 (m, 2H, H-3 and H-5 pyridine); 6.82 (d, 1H, H-3). Anal.
C, H, N.
5.2.4. 8-(Thien-2-yl)pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide
(6)
From 1,18 and 2-thiophen boronic acid, 3 h, 70 C. Yellow crys-
tals; TLC eluent: diisopropyl ether/cyclohexane 8:3 v/v; 1H NMR
(CDCl3) d 8.59 (d, 1H, H-9); 8.57 (d, 2H, H-6); 8.14 (d, 1H, H-2);
7.87 (dd, 1H, H-7); 7.69 (d, 1H, H-5 thiophene); 7.57 (d, 1H, H-3
thiophene); 7.22 (m, 1H, H-4 thiophene); 6.79 (d, 1H, H-3). Anal.
C, H, N.
5.2.5. 8-(Thien-3-yl)pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide
(7)
From 1,18 and 3-thiophen boronic acid, 1.5 h, room tempera-
ture. Yellow crystals; TLC eluent: diisopropyl ether/cyclohexane
8:3 v/v; 1H NMR (CDCl3) d 8.49 (m, 2H, H-6 and H-9); 8.05 (d,
1H, H-2); 7.78 (m, 2H, H-7 and H-2 thiophene); 7.51 (m, 1H, H-4
thiophene); 7.45 (m, 1H, H-5 thiophene); 6.69 (d, 1H, H-3). Anal.
C, H, N.
5.2.6. 8-(N-Boc-pyrrol-2-yl)pyrazolo[5,1-c][1,2,4]benzotriazine
5-oxide (9)
From 1,18 and N(Boc)pyrrole-2-boronic acid 3 h, 60–70 C, in
toluene. Red crystals; TLC eluent: toluene/ethyl acetate/acetic acid
8:2:1 v/v/v; 1H NMR (CDCl3) d 8.45 (m, 2H, H-6 and H-9); 8.02 (d,
1H, H-2); 7.73 (dd, 1H, H-7); 7.40 (m, 1H, H-3 pyrrole); 6.65 (d, 1H,
H-3); 6.50 (m, 1H, H-5, pyrrole); 6.30 (m, 1H, H-4 pyrrole); 1.40 (s,
9H, (CH3)3). Anal. C, H, N.
5.2.7. 3-(Thien-3-yl)-8-phenylpyrazolo[5,1-c][1,2,4]-
benzotriazine 5-oxide (19)
From 2,22 and phenylboronic acid, 8 h, 50–60 C. Red crystals;
TLC eluent: diisopropyl ether/cyclohexane 8:3 v/v; 1H NMR (CDCl3)
d 8.62 (d, 1H, H-6); 8.59 (d, 1H, H-9); 8.36 (s, 1H, H-2); 7.93 (d, 1H,
Figure 5. Compounds 41 (in two orientations A, B) and compound 32 in the pharmacophoric model performed by ADLR. Contribute of ester group to receptor anchorage.
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H-2 thiophene); 7.88 (dd, 1H, H-7); 7.80 (d, 2H, H-2 and H-6 phe-
nyl); 7.68 (d, 1H, H-4 thiophene); 7.55 (m, 3H, H-3, H-4 and H-5
phenyl); 7.46 (m, 1H, H-5 thiophene). Anal. C, H, N.
5.2.8. 3-(Thien-3-yl)-8-(4-Methoxyphenyl)pyrazolo[5,1-
c][1,2,4]-benzotriazine 5-oxide (20)
From 2,22 and 4-methoxyphenylboronic acid, 4 h, 60–70 C. Red
crystals; TLC eluent: diisopropyl ether/cyclohexane 8:3 v/v; 1H
NMR (DMSO-d6) d 8.75 (s, 1H, H-2); 8.47 (m, 2H, H-6 and H-9);
8.05 (dd, 1H, H-7); 8.00 (d, 1H, H-2 thiophene); 7.93 (d, 2H, H-20
and H-60 phenyl); 7.79 (d, 1H, H-4 thiophene); 7.72 (m, 1H, H-5 thi-
ophene); 7.15 (d, 2H, H-30 and H-50 phenyl). Anal. C, H, N.
5.2.9. 3-(Thien-3-yl)-8-(thien-2-yl)pyrazolo[5,1-c][1,2,4]-
benzotriazine 5-oxide (21)
From 2,22 and 2-thiophenboronic acid, 2 h, room temperature.
Red crystals; TLC eluent: diisopropyl ether/cyclohexane 8:3 v/v;
1H NMR (CDCl3) d 8.58 (m, 2H, H-6 and H-9); 8.36 (s, 1H, H-2);
7.93 (m, 1H, H-2, 3-thiophene); 7.85 (dd, 1H, H-7); 7.68 (m, 2H,
H-4, 3-thiophene and H-3, 8-thiophene); 7.58 (dd, 1H, H-5, 8-thio-
phene); 7.46 (dd, 1H, H-5, 3-thiophene); 7.21 (dd, 1H, H-4, 8-thio-
phene). Anal. C, H, N.
5.2.10. 3-(Thien-3-yl)-8-(thien-3-yl)pyrazolo[5,1-c][1,2,4]-
benzotriazine 5-oxide (22)
From 2,22 and 3-thiophenboronic acid, 3 h, 80 C, in toluene. Red
crystals; TLC eluent: diisopropyl ether/cyclohexane 8:3 v/v; 1H
NMR (CDCl3) d 8.59 (m, 2H, H-6 and H-9); 8.36 (s, 1H, H-2); 7.93
(m, 1H, H-2, 3-thiophene); 7.86 (m, 2H, H-7 and H-2, 8-thiophene);
7.69 (dd, 1H, H-4, 3-thiophene); 7.61 (dd, 1H, H-4, 8-thiophene);
7.54 (dd, 1H, H-5, 8-thiophene); 7.46 (dd, 1H, H-5, 3-thiophene).
Anal. C, H, N.
5.2.11. 3-(Thien-3-yl)-8-(N-Boc-pyrrol-2-yl)pyrazolo[5,1-c]-
[1,2,4]benzotriazine 5-oxide (24)
From 2,22 and N(Boc)pyrrole-2-boronic acid, 3 h, 60–70 C, in
toluene. Red crystals; TLC eluent: toluene/ethyl acetate/acetic acid
8:2:1 v/v/v; 1H NMR (DMSO-d6) d 8.73 (s, 1H, H-2); 8.40 (d, 1H, H-
6), 8.21 (d, 1H, H-9); 7.99 (m, 1H, H-2, 3-thiophene); 7.75 (m, 3H,
H-7 and H-5, 3-thiophene and H-3 pyrrole); 7.57 (m, 1H, H-4, 3-
thiophene); 6.70 (m, 1H, H-5, pyrrole); 6.51 (m, 1H, H-4 pyrrole);
1.40 (s, 9H, (CH3)3). Anal. C, H, N.
5.2.12. 3-(N-Boc-pyrrol-2-yl)-8-(thien-3-yl)pyrazolo[5,1-c]-
[1,2,4]benzotriazine 5-oxide (27)
From 15 (see below) and N(Boc)pyrrole-2-boronic acid, 3 h,
60–70 C, in toluene. Red crystals; TLC eluent: toluene/ethyl
acetate/acetic acid 8:2:1 v/v/v; 1H NMR (DMSO-d6) d 8.51 (d, 1H,
H-9); 8.38 (m, 1H, H-2 thiophene); 8.36 (d, 1H, H-6); 8.32 (s, 1H,
H-2); 8.18 (dd, 1H, H-7); 7.80 (m, 1H, H-5, thiophene); 7.70 (m,
1H, H-4 thiophene); 7.39 (m, 1H, H-3 pyrrole); 6.40 (m, 1H, H-5,
pyrrole); 6.30 (m, 1H, H-4 pyrrole); 1.30 (s, 9H, (CH3)3). Anal. C,
H, N.
5.2.13. 3-(2-Thienylmethoxycarbonyl)-8-(4-methoxy-
phenyl)pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide (32)
From 31,22 and 4-methoxyphenylboronic acid, 8 h, room tem-
perature. Yellow crystals; TLC eluent: toluene/ethyl acetate 8:3 v/
v; 1H NMR (CDCl3) d 8.68 (s, 1H, H-2); 8.51 (d, 1H, H-9); 8.49 (d,
1H, H-6); 8.12 (dd, 1H, H-7); 7.95 (d, 2H, H-2 and H-6 phenyl);
7.60 (d, 1H, H-5 thiophene); 7.30 (d, 1H, H-3 thiophene); 7.60 (d,
2H, H-3 and H-5 phenyl); 7.08 (m, 1H, H-5 thiophene); 5.52 (s,
2H, CH2); 3.80 (s, 3H, CH3). Anal. C, H, N.
5.2.14. 3-(2-Thienylmethoxycarbonyl)-8-(N-Boc-pyrrol-2-yl)-
pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide (33)
From 31,22 and N(Boc)pyrrole-2-boronic acid, 3 h, refluxing
temperature, in toluene. Yellow crystals; TLC eluent: toluene/ethyl
acetate/acetic acid 8:2:1 v/v/v; 1H NMR (DMSO-d6) d 8.67 (s, 1H, H-
2); 8.40 (d, 1H, H-6), 8.23 (d, 1H, H-9); 7.82 (dd, 1H, H-7); 7.60 (m,
1H, H-5 thiophene); 7.55 (m, 1H, H-3 pyrrole); 7.30 (m, 1H, H-3, 3-
thiophene); 7.01 (m, 1H, H-4 thiophene); 6.71 (m, 1H, H-5, pyr-
role); 6.42 (m, 1H, H-4 pyrrole); 5.51 (s, 2H, CH2); 1.40 (s, 9H,
(CH3)3). Anal. C, H, N.
5.2.15. 3-(Fur-2-ylcarbonyl)-8-(4-methoxyphenyl)pyrazolo[5,1-
c][1,2,4]benzotriazine 5-oxide (35)
From 30 (see below), and 4-methoxyphenylboronic acid, 12 h,
room temperature. Yellow crystals; TLC eluent: toluene/ethyl ace-
tate 8:3 v/v; 1H NMR (CDCl3) d 8.91 (s, 1H, H-2); 8.55 (d, 1H, H-9);
8.40 (d, 1H, H-6); 8.18 (m, 2H, H-7 and H-5 furane); 7.98 (d, 2H, H-
2 and H-6 phenyl); 7.61 (d, 1H, H-3 furane); 7.18 (d, 2H, H-3 and H-
5 phenyl); 6.82 (m, 1H, H-4 furane); 3.80 (s, 3H, CH3). Anal. C, H, N.
5.2.16. 3-(Fur-2-ylcarbonyl)-8-(N-Boc-pyrrol-2-yl)pyrazolo[5,1-
c][1,2,4]benzotriazine 5-oxide (36)
From 30 and N(Boc)pyrrole-2-boronic acid, 3 h, refluxing tem-
perature, in tetrahydrofurane. Yellow crystals; TLC eluent: tolu-
ene/ethyl acetate/acetic acid 8:2:1 v/v/v; 1H NMR (DMSO-d6) d
8.91 (s, 1H, H-2); 8.42 (d, 1H, H-6), 8.30 (d, 1H, H-9); 8.12 (d, 1H,
H-5 furane); 7.82 (dd, 1H, H-7); 7.62 (m, 1H, H-3 furane); 7.58
(m, 1H, H-3 pyrrole); 6.82 (m, 1H, H-4, furane); 6.72 (m, 1H, H-5,
pyrrole); 6.42 (m, 1H, H-4 pyrrole); 1.40 (s, 9H, (CH3)3). Anal. C,
H, N.
5.3. 3-(Fur-2-ylcarbonyl)-8-iodopyrazolo[5,1-c][1,2,4]-
benzotriazine 5-oxide (30)
The starting material 29,22 (0.22 mmol) was reacted with
2.5 mL of thionyl chloride and maintained at refluxing temperature
for 1 h. The final solution was evaporated in vacuo and the corre-
sponding 3-carbonylchloride intermediate was utilized as that in
the next Friedel–Craft reaction. Dichloromethane (10 mL), SnCl4
(0.2 mL), and furane (0.2 mL) were added to the carbonylchloride
residue and the reaction was heated at 40–50 C, monitoring by
TLC (eluent: toluene/ethyl acetate/acetic acid 8:2:1 v/v/v). The
reaction was quenched with HCl 1:1, diluted with dichlorometh-
ane and the organic phase separated. The dichloromethane phase
was washed with a saturated solution of sodium bicarbonate, dried
over sodium sulfate anhydrous and evaporated. The final residue
was purified by chromatography column (eluent: toluene/ethyl
acetate/acetic acid 8:2:1 v/v/v) and 30 was eluted as the fast band.
Yellow crystals; 1H NMR (DMSO-d6) d 8.91 (s, 1H, H-2); 8.78 (d, 1H,
H-9); 8.18 (m, 3H, H-7, H-6 and H-5 furane); 7.61 (d, 1H, H-3 fur-
ane); 6.82 (m, 1H, H-4 furane).
5.4. General procedure for the synthesis of derivatives 8, 23, 26,
and 39
A solution of potassium 2-furantrifluoroborate (60 mg,
0.34 mmol), PdCl2(dppf)CH2Cl2 (20 mg), triethylamine (0.1 mL)
and the suitable starting materials: 1,18 2,22, 15, 38,22 (0.2 mmol)
in n-propyl alcohol (10 mL) was stirred at reflux for 3 h. The reac-
tion was monitored by TLC (eluent: toluene/ethyl acetate/acetic
acid 8:2:1 v/v/v) and when the staring material disappeared, was
cooled to room temperature, and diluted with water (15 mL). The
appropriate work up of the final suspension gave the desired final
products 8, 23, 26, and 39.
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5.4.1. 8-(Fur-2-yl)pyrazolo[5,1-c][1,2,4]benzotriazine 5-oxide
(8)
From 1,18 the final suspension was extracted with ethyl acetate
and dried over sodium sulfate anhydrous. Evaporation of solution
gave orange residue. 1H NMR (DMSO-d6) d 8.45 (m, 2H, H-6 and
H-9); 8.20 (d, 1H, H-2); 8.08 (m, 2H, H-7 and H-5 furane); 7.58
(m, 1H, H-3 furane); 6.92 (d, 1H, H-3); 6.80 (m, 1H, H-4 furane).
Anal. C, H, N.
5.4.2. 3-(Thien-3-yl)-8-(fur-2-yl)pyrazolo[5,1-c][1,2,4]benzo-
triazine 5-oxide (23)
From 2,22 the final suspension was extracted with ethyl
acetate (10 mL  3), dried over sodium sulfate anhydrous and
evaporated in vacuo and the residue recrystallized. Red crystals;
1H NMR (DMSO-d6) d 8.78 (s, 1H, H-2); 8.49 (m, 2H, H-6 and
H-9); 8.08 (d, 1H, H-7); 8.02 (s, 1H, H-2, thiophene); 8.00 (d,
1H, H-5 furane); 7.77 (m, 1H, H-4, thiophene); 7.72 (m, 1H,
H-5, thiophene); 7.58 (d, 1H, H-3 furane); 6.78 (m, 1H, H-4
furane). Anal. C, H, N.
5.4.3. 3-(Fur-2-yl)-8-(thien-3-yl)pyrazolo[5,1-c][1,2,4]benzo-
triazine 5-oxide (26)
From 15. The precipitate was filtered and purified by silica gel
chromatography (eluting with toluene/ethyl acetate/acetic acid
8:2:1 v/v/v). Red crystals; 1H NMR (DMSO-d6) d 8.60 (s, 1H, H-2);
8.58 (d, 1H, H-9); 8.45 (m, 2H, H-6 and H-2 thiophene); 8.12 (dd,
1H, H-7); 7.88 (m, 1H, H-5, thiophene); 7.80 (m, 2H, H-4 thiophene
and H-5 furane); 6.85 (d, 1H, H-3 furane); 6.68 (m, 1H, H-4 furane).
Anal. C, H, N.
5.4.4. Ethyl 1-(2-nitro-5-(fur-2-yl)phenyl)-5-aminopyrazol-4-
carboxylate (39)
From 38,22 dark-yellow crystals; 1H NMR (DMSO-d6) d 8.21 (d,
1H, H-30); 8.01 (dd, 1H, H-40); 7.97 (d, 1H, H-60); 7.93 (s, 1H, H-5
furane); 7.70 (s, 1H, H-3); 7.41 (d, 1H, H-3 furane); 6.73 (m, 1H,
H-4 furane); 6.57 (br s, 2H, NH2, exch.); 4.22 (q, 2H, CH2); 1.35 (t,
3H, CH3). Anal. C, H, N.
5.5. General procedure for the synthesis of derivatives 10 and
12–17
A solution of appropriate starting material 3–9 (0.30 mmol) in
acetonitrile (10 mL) was added of iodine (0.18 mmol) and cerium
ammonium nitrate (CAN, 0.18 mmol) and maintained at room
temperature for 45 min. The final red solution was evaporated
under reduced pressure and the residue was washed with a 10% so-
dium hydroxide solution, the precipitate filtered and recrystallized
by suitable solvent.
5.5.1. 3-Iodo-8-(2-methoxyphenyl)pyrazolo[5,1-
c][1,2,4]benzotriazine 5-oxide (10)
From 3. Orange crystals; TLC eluent: toluene/ethyl acetate/ace-
tic acid 8:2:1 v/v/v; 1H NMR (DMSO-d6) d 8.46 (d, 1H, H-6); 8.41 (d,
1H, H-9); 8.34 (s, 1H, H-2); 7.87 (dd, 1H, H-7); 7.53 (m, 2H, H-4 and
H-6 phenyl); 7.25 (d, 1H, H-3 phenyl); 7.16 (t, 1H, H-5 phenyl);
3.85 (s, 3H, OCH3). Anal. C, H, N.
5.5.2. 3-Iodo-8-(4-methoxyphenyl)pyrazolo[5,1-c][1,2,4]benzo-
triazine 5-oxide (12)
From 4. Orange crystals; TLC eluent: toluene/ethyl acetate/ace-
tic acid 8:2:1 v/v/v; 1H NMR (DMSO-d6) d 8.46 (m, 2H, H-2 and H-
6); 8.40 (d, 1H, H-9); 8.05 (dd, 1H, H-7); 7.92 (d, 2H, H-2 and H-6
phenyl); 7.13 (d, 2H, H-3 and H-5 phenyl); 3.85 (s, 3H, OCH3). Anal.
C, H, N.
5.5.3. 3-Iodo-8-(4-pyridyl)pyrazolo[5,1-c][1,2,4]benzotriazine 5-
oxide (13)
From 5. Orange crystals; TLC eluent: toluene/ethyl acetate/ace-
tic acid 8:2:1 v/v/v; 1H NMR (DMSO-d6) d 8.79 (d, 2H, H-2 and H-6
pyridine); 8.64 (d, 1H, H-9); 8.55 (d, 1H, H-6); 8.44 (s, 1H, H-2);
8.15 (dd, 1H, H-7); 7.98 (m, 2H, H-3 and H-5 pyridine). Anal. C,
H, N.
5.5.4. 3-Iodo-8-(thien-2-yl)pyrazolo[5,1-c][1,2,4]benzotriazine
5-oxide (14)
From 6. Orange crystals; TLC eluent: diisopropyl ether/cyclo-
hexane 8:3 v/v; 1H NMR (CDCl3) d 8.58 (m, 2H, H-6 and H-9);
8.14 (s, 1H, H-2); 7.88 (dd, 1H, H-7); 7.69 (d, 1H, H-5 thiophene);
7.57 (d, 1H, H-3 thiophene); 7.22 (m, 1H, H-4 thiophene). Anal.
C, H, N.
5.5.5. 3-Iodo-8-(thien-3-yl)pyrazolo[5,1-c][1,2,4]benzotriazine
5-oxide (15)
From 7. Orange crystals; TLC eluent: diisopropyl ether/cyclo-
hexane 8:3 v/v; 1H NMR (CDCl3) d 8.57 (m, 2H, H-6 and H-9);
8.14 (s, 1H, H-2); 7.88 (m, 2H, H-7 and H-2 thiophene); 7.59 (m,
1H, H-4 thiophene); 7.45 (m, 1H, H-5 thiophene). Anal. C, H, N.
5.5.6. 3-Iodo-8-(Fur-2-yl)pyrazolo[5,1-c][1,2,4]benzotriazine 5-
oxide (16)
From 8. Orange crystals; TLC eluent: diisopropyl ether/cyclo-
hexane 8:3 v/v; 1H NMR (DMSO-d6) d 8.47 (m, 3H, H-6, H-2, and
H-9); 8.05 (dd, 1H, H-7); 7.98 (m, 1H, H-5 furane); 7.52 (m, 1H,
H-3 furane); 6.79 (m, 1H, H-4 furane). Anal. C, H, N.
5.5.7. 3-Iodo-8-(N-Boc-pyrrol-2-yl)pyrazolo[5,1-c][1,2,4]benzo-
triazine 5-oxide (17)
From 9. Orange crystals; TLC eluent: toluene/ethyl acetate/ace-
tic acid 8:2:1 v/v/v; 1H NMR (DMSO-d6) d 8.44 (m, 3H, H-2, H-6 and
H-9); 7.85 (d, 1H, H-7); 7.79 (m, 1H, H-3 pyrrole); 6.72 (m, 1H, H-5,
pyrrole); 6.42 (m, 1H, H-4 pyrrole); 1.40 (s, 9H, (CH3)3). Anal. C,
H, N.
5.6. 3-Iodo-8-(2-hydroxyphenyl)pyrazolo[5,1-c][1,2,4]benzo-
triazine 5-oxide (11)
A solution of 10 (0.24 mmol) in dichloromethane (15 mL) was
reacted with BBr3 (0.3 mL) at refluxing temperature until the start-
ing material disappeared in TLC (eluent: toluene/ethyl acetate/ace-
tic acid 8:2:1). Then the final solution was treated with a 10%
sodium hydroxide solution and the organic layer eliminated. The
aqueous phase, after acidification (HCl 1:1) was extracted with
ethyl acetate, dried and evaporated dryness obtained a yellow res-
idue that was purified by recrystallization. 1H NMR (DMSO-d6) d
10.2 (br s, 1H, OH); 8.55 (d, 1H, H-9); 8.46 (d, 1H, H-6); 8.34 (s,
1H, H-2); 7.95 (dd, 1H, H-7); 7.50 (d, 1H, H-3 phenyl); 7.35 (t,
1H, H-5 phenyl); 7.01 (d, 1H, H-6 phenyl); 7.00 (t, 1H, H-4 phenyl).
Anal. C, H, N.
5.7. General procedure for the synthesis of derivatives18, 25, 28,
34 and 37
To a mixture of starting material 17, 24, 27, 33, and 36
(0.15 mmol) and anhydrous THF (2 mL) was added a solution of so-
dium methoxide in methanol (2 mL of a 0.43 M solution). The mix-
ture was allowed to stir 1 h at room temperature and then treated
with water. The resulting suspension was worked up and the row
product recrystallized by suitable solvent.
In case of starting material 33 a trans-esterification occurred
and the final product was the 3-methyl ester derivative 34.
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5.7.1. 3-Iodo-8-(pyrrol-2-yl)pyrazolo[5,1-c][1,2,4]benzotriazine
5-oxide (18)
From 17. Red crystals; TLC eluent: toluene/ethyl acetate/acetic
acid 8:2:1 v/v/v; 1H NMR (DMSO-d6) d 12.00 (br s, 1H, NH, exch.);
8.43 (s, 1H, H-2); 8.40 (d, 1H, H-9); 8.25 (d, 1H, H-6); 8.00 (dd, 1H,
H-7); 7.10 (m, 1H, H-3 pyrrole); 7.05 (m, 1H, H-5, pyrrole); 6.30 (m,
1H, H-4 pyrrole). Anal. C, H, N.
5.7.2. 3-(Thien-3-yl)-8-(pyrrol-2-yl)pyrazolo[5,1-c][1,2,4]benzo-
triazine 5-oxide (25)
From 24. Red crystals; TLC eluent: toluene/ethyl acetate/acetic
acid 8:2:1 v/v/v; 1H NMR (DMSO-d6) d 12.00 (br s, 1H, NH, exch.);
8.73 (s, 1H, H-2); 8.50 (d, 1H, H-9); 8.35 (d, 1H, H-6); 8.00 (m, 2H,
H-7 and H-2, 3-thiophene); 7.78 (m, 1H, H-5, 3-thiophene); 7.70
(m, 1H, H-5, 3-thiophene); 7.12 (m, 1H, H-5, pyrrole); 7.01 (m,
1H, H-4 pyrrole); 6.30 (m, 1H, H-3 pyrrole). Anal. C, H, N.
5.7.3. 3-(Pyrrol-2-yl)-8-(thien-3-yl)pyrazolo[5,1-c][1,2,4]benzo-
triazine 5-oxide (28)
From 27. Red crystals; TLC eluent: toluene/ethyl acetate/acetic
acid 8:2:1 v/v/v; 1H NMR (DMSO-d6) d 11.35 (br s, 1H, NH, exch.);
8.51 (m, 2H, H-6 and H-2); 8.42 (m, 2H, H-9 and H-2 thiophene);
8.01 (dd, 1H, H-7); 7.83 (m, 1H, H-5, thiophene); 7.70 (m, 1H, H-
4 thiophene); 6.90 (m, 1H, H-3 pyrrole); 6.60 (m, 1H, H-5, pyrrole);
6.18 (m, 1H, H-4 pyrrole). Anal. C, H, N.
5.7.4. 3-Methoxycarbonyl-8-(pyrrol-2-yl)pyrazolo[5,1-c][1,2,4]-
benzotriazine 5-oxide (34)
From 33, in reaction conditions a trans-esterification occurred.
Red crystals; TLC eluent: toluene/ethyl acetate/acetic acid 8:2:1
v/v/v; 1H NMR (DMSO-d6) d 12.1 (br s, 1H, NH, exch.); 8.67 (s,
1H, H-2); 8.55 (d, 1H, H-9); 8.38 (d, 1H, H-6), 8.08 (dd, 1H, H-7);
7.18 (m, 1H, H-3 pyrrole); 7.08 (m, 1H, H-5, pyrrole); 6.30 (m,
1H, H-4 pyrrole); 3.90 (s, 3H, CH3). Anal. C, H, N.
5.7.5. 3-(Fur-2-ylcarbonyl)-8-(pyrrol-2-yl)pyrazolo[5,1-c][1,2,4]-
benzotriazine 5-oxide (37)
From 36. TLC eluent: toluene/ethyl acetate/acetic acid 8:2:1 v/v/
v; 1H NMR (DMSO-d6) d 12.00 (br s, 1H, NH, exch.); 8.91 (s, 1H, H-
2); 8.60 (d, 1H, H-9); 8.38 (d, 1H, H-6), 8.12 (m, 2H, H-7 and H-5
furane); 7.62 (m, 1H, H-3 furane); 7.15 (m, 1H, H-3 pyrrole); 7.08
(m, 1H, H-5, pyrrole); 6.80 (m, 1H, H-4 furane); 6.30 (m, 1H, H-4
pyrrole). Anal. C, H, N.
5.8. 3-Carboxy-8-(fur-2-yl)pyrazolo[5,1-c][1,2,4]benzotriazine
5-oxide (40)
A solution of 39 (0.5 mmol) in diglyme (5 mL) was added of
25 mL of 10% sodium hydroxide solution and was kept at 50–
60 C until the starting material disappeared, monitoring by TLC.
The final suspension was treated with hydrochloric acid and the fil-
tration of the precipitate afforded to the acid derivative 40. The
crude products were then recrystallized by suitable solvent. Yellow
crystals; TLC eluent: toluene/ethyl acetate/acetic acid 8:2:1 v/v/v;
1H NMR (DMSO-d6) d 12.9 (br s, 1H, OH, exch.); 8.61 (s, 1H, H-3);
8.51 (d, 1H, H-9); 8.48 (d, 1H, H-6); 8.15 (dd, 1H, H-7); 8.03 (d,
1H, H-5 furane); 7.60 (d, 1H, H-3 furane); 6.80 (m, 1H, H-4 furane).
Anal. C, H, N.
5.9. 3-(2-Thienylmethoxycarbonyl)-8-(fur-2-yl)pyrazolo[5,1-c]-
[1,2,4]benzotriazine 5-oxide (41)
A suspension of the acid 40 (0.337 mmol) in anhydrous THF and
triethyl amine (1:3.5) was maintained at 0 C in ice bath for 300. To
the suspension was added i-butylchloroformate (0.2 mL) and
maintained under stirring for 1 h, from 0 C to room temperature,
to permit the anhydride to form. The 2-thiophen methanol was
added in excess (0.2 mL) and the reaction was monitored by TLC
(eluent: toluene/ethyl acetate 8:2). The final suspension was di-
luted with water and extracted with ethyl acetate which was in
turn washed with sodium hydrogen carbonate and, after the nor-
mal work up, the residue was purified by chromatography column.
Yellow crystals. 1H NMR (DMSO-d6) d 8.68 (s, 1H, H-2); 8.52 (d, 1H,
H-9); 8.49 (d, 1H, H-6); 8.14 (dd, 1H, H-7); 8.03 (d, 1H, H-5 furane);
7.60 (m, 2H, H-5 thiophene and H-3 furane); 7.30 (m, 1H, H-3, 3-
thiophene); 7.06 (m, 1H, H-4 thiophene); 6.80 (m, 1H, H-4 furane);
5.55 (s, 2H, CH2). Anal. C, H, N.
5.10. 3-(Fur-2-ylcarbonyl)-8-(fur-2-yl)pyrazolo[5,1-c][1,2,4]-
benzotriazine 5-oxide (42)
To a mixture of acid 40 (0.20 mmol) and trichloroacetonitrile
(0.60 mmol) in dichloromethane (10 mL) was added triphenyl-
phosphine (0.60 mmol) in dichloromethane (1.0 mL) dropwise at
room temperature. The reaction mixture was stirred at room tem-
perature for 2 h until the starting material disappeared in TLC (elu-
ent: toluene/ethyl acetate/acetic acid 8:2:1 v/v/v). The reaction
was then treated with SnCl4 (0.1 mL) followed furane (0.1 mL).
After 300 the solution was treated with water and the organic layer
was separated, dried and evaporated to dryness. The residue was
recovered by diisopropyl ether and recrystallized by suitable sol-
vent. Yellow crystals. TLC eluent: toluene/ethyl acetate/acetic acid
8:2:1 v/v/v; 1H NMR (DMSO-d6) d 8.91 (s, 1H, H-2); 8.58 (d, 1H, H-
9); 8.50 (d, 1H, H-6), 8.16 (dd, 1H, H-7); 8.12 (m, 1H, H-5, 2-furoyl);
8.06 (m, 1H, H-5 furane); 7.62 (m, 2H, H-3, 2-furoyl and furane);
6.83 (m, 2H, H-4, 2-furoyl and furane). Anal. C, H, N.
5.11. Radioligand binding assay
[3H]Ro15-1788 (specific activity 78.8 Ci/mmol) was obtained
from Perkin–Elmer.30,31 All the other chemicals, which were of re-
agent grade, were obtained from commercial suppliers.
Bovine cerebral cortex membranes were prepared as previously
described. The membrane preparations were diluted with 50 mM
Tris–citrate buffer pH 7.4, and used in the binding assay. Protein
concentration was assayed using the method of Lowry et al.32
[3H]Ro 15-1788 binding studies were performed as previously re-
ported.20 At least six different concentrations of each compound
were used. The data of n = 5 experiments carried out in triplicate
were analyzed by means of an iterative curve-fitting procedure
(program Prism, GraphPad, San Diego, CA), which provided IC50,
Ki, and SEM values for tested compounds, the Ki values being calcu-
lated from the Cheng and Prusoff equation.33
Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bmc.2011.04.009.
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